Pomerantz Law Firm Investigates Potential Securities Fraud Involving ADMA Biologics and Its Investors

Investigation Launched by Pomerantz LLP

Pomerantz LLP, a leading law firm specializing in class action litigation, has initiated an investigation concerning claims made on behalf of investors in ADMA Biologics, Inc. (NASDAQ: ADMA). The inquiry centers around allegations of securities fraud and potentially illegal business conduct by certain officers and directors of the company.

On March 24, 2026, Culper Research issued a report suggesting that the growth figures reported by ADMA were misleading, supposedly driven by "channel stuffing" and an undisclosed related-party distributor. According to the report, ADMA’s true revenue figures reflected a decline of about 3% in 2025 instead of the reported increase of 20%. The release of this information resulted in a significant drop in ADMA's share price, which fell by $2.26, representing a loss of 16.63%, concluding the trading day at $11.33.

The following events compounded the situation for ADMA. On March 26, Cantor Fitzgerald downgraded the company, critiquing its response to the claims made in the Culper report, which they found insufficiently detailed. This downgrade precipitated another decline in the stock price, dropping it further by $1.34, or 13.91%, to achieve a closing price of $8.29. Notably, stock price volatility – especially following public allegation and subsequent downgrades – can erode investor trust and raise severe compliance questions for the company’s leadership.

Pomerantz LLP is renowned for its history and commitment to protecting investors' rights against securities fraud, misconduct, and breaches of fiduciary duty. Founded by the late Abraham L. Pomerantz, oftentimes referred to as the dean of the class action bar, the firm has successfully pursued numerous cases leading to multi-million dollar recoveries for class members. With offices located in critical global markets, including New York, Chicago, London, and more, Pomerantz is deeply rooted in reiterating its resolve against corporate wrongdoing.

Potentially impacted investors are encouraged to reach out to the firm's attorney, Danielle Peyton, via email at [email protected] or by calling 646-581-9980, extension 7980, to discuss possible actions they can take regarding this situation.

With the ongoing evolution of the legal landscape regarding securities investigations, it is vital for investors in ADMA Biologics to stay informed about the potential risks and available remedies as the situation develops. Pomerantz’s litigation initiative aims to offer a crucial avenue for investors feeling vulnerable following these alarming claims and market reactions. As always, previous outcomes do not guarantee similar results, and seeking legal assistance is fundamental in navigating these complex financial disputes.